RNA nanomedicines: The next generation drugs?

Current Opinion in Biotechnology

Volumn 39, Issue , 2016, Pages 28-34

  Singh, Manu Smriti ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; GENE EXPRESSION; MOLECULES; NUCLEIC ACIDS; TUMORS;

ADVERSE EFFECT; CANCER CELLS; CANCEROUS CELLS; PERSONALIZED MEDICINES; RNA INTERFERENCE; RNA MOLECULES; RNA THERAPEUTICS; TUMOR MICROENVIRONMENT;

RNA;

ALN VSP 02; ALNPCS 02; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATU 027; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DCR MYC; HYALURONIC ACID; LIPOSOME; MACROGOL; MICRORNA 122; MIRAVIRSEN; NANOCARRIER; ND L 02; PATISIRAN; REVUSIRAN; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TKM 080301; UNCLASSIFIED DRUG; DRUG; DRUG CARRIER;

ACCESSORY CELL; CANCER CELL; CANCER INHIBITION; CANCER STEM CELL; CHEMICAL MODIFICATION; ENDOCYTOSIS; HUMAN; HYPOXIA; LIPOSOMAL DELIVERY; METASTASIS INHIBITION; MICELLE; NANOMEDICINE; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNAI THERAPEUTICS; SOLID TUMOR; TUMOR MICROENVIRONMENT; CHEMISTRY; METABOLISM; NEOPLASMS; PROCEDURES; TRANSLATIONAL RESEARCH;

DRUG CARRIERS; HUMANS; NANOMEDICINE; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; RNA, SMALL INTERFERING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84953310429     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2015.12.011     Document Type: Review

References (61)

1. Peer D. Harnessing RNAi nanomedicine for precision therapy. Mol Cell Therap 2014, 2:5.
2. Haussecker D. Current issues of RNAi therapeutics delivery and development. J Control Release 2014, 195:49-54.
3. Ozcan G., Ozpolat B., Coleman R.L., Sood A.K., Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015.
4. Daka A., Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 2012, 64:1508-1521.
5. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11:59-67.
6. Meade B.R., Gogoi K., Hamil A.S., Palm-Apergi C., van den Berg A., Hagopian J.C., Springer A.D., Eguchi A., Kacsinta A.D., Dowdy C.F., Presente A., Lonn P., Kaulich M., Yoshioka N., Gros E., Cui X.S., Dowdy S.F. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat Biotechnol 2014, 32:1256-1261.
7. Wu S.Y., Yang X., Gharpure K.M., Hatakeyama H., Egli M., McGuire M.H., Nagaraja A.S., Miyake T.M., Rupaimoole R., Pecot C.V., Taylor M., Pradeep S., Sierant M., Rodriguez-Aguayo C., Choi H.J., Previs R.A., Armaiz-Pena G.N., Huang L., Martinez C., Hassell T., Ivan C., Sehgal V., Singhania R., Han H.D., Su C., Kim J.H., Dalton H.J., Kovvali C., Keyomarsi K., McMillan N.A., Overwijk W.W., Liu J., Lee J.S., Baggerly K.A., Lopez-Berestein G., Ram P.T., Nawrot B., Sood A.K. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 2014, 5:3459.
8. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
9. Dahlman J.E., Barnes C., Khan O.F., Thiriot A., Jhunjunwala S., Shaw T.E., Xing Y., Sager H.B., Sahay G., Speciner L., Bader A., Bogorad R.L., Yin H., Racie T., Dong Y., Jiang S., Seedorf D., Dave A., Singh Sandhu K., Webber M.J., Novobrantseva T., Ruda V.M., Lytton-Jean A.K., Levins C.G., Kalish B., Mudge D.K., Perez M., Abezgauz L., Dutta P., Smith L., Charisse K., Kieran M.W., Fitzgerald K., Nahrendorf M., Danino D., Tuder R.M., von Andrian U.H., Akinc A., Panigrahy D., Schroeder A., Koteliansky V., Langer R., Anderson D.G. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol 2014, 9:648-655.
10. Sun Y., Kim H.S., Saw P.E., Jon S., Moon W.K. Targeted therapy for breast cancer stem cells by liposomal delivery of siRNA against fibronectin EDB. Adv Healthc Mater 2015, 4:1675-1680.
11. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
12. Cohen K., Emmanuel R., Kisin-Finfer E., Shabat D., Peer D. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 2014, 8:2183-2195.
13. Wu X., Chen J., Wu M., Zhao J.X. Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics 2015, 5:322-344.
14. Wong S.C., Klein J.J., Hamilton H.L., Chu Q.L., Frey C.L., Trubetskoy V.S., Hegge J., Wakefield D., Rozema D.B., Lewis D.L. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Therap 2012, 22:380-390.
15. Landesman-Milo D., Ramishetti S., Peer D. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev 2015, 34:291-301.
16. Cohen Z.R., Ramishetti S., Peshes-Yaloz N., Goldsmith M., Wohl A., Zibly Z., Peer D. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 2015, 9:1581-1591.
17. Ramishetti S., Kedmi R., Goldsmith M., Leonard F., Sprague A.G., Godin B., Gozin M., Cullis P.R., Dykxhoorn D.M., Peer D. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 2015.
18. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010, 31:6867-6875.
19. Landesman-Milo D., Peer D. Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv Transl Res 2014, 4:96-103.
20. Mizrahy S., Goldsmith M., Leviatan-Ben-Arye S., Kisin-Finfer E., Redy O., Srinivasan S., Shabat D., Godin B., Peer D. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 2014, 6:3742-3752.
21. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
22. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995, 92:7297-7301.
23. Sahay G., Querbes W., Alabi C., Eltoukhy A., Sarkar S., Zurenko C., Karagiannis E., Love K., Chen D., Zoncu R., Buganim Y., Schroeder A., Langer R., Anderson D.G. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013, 31:653-658.
24. Khan A.A., Betel D., Miller M.L., Sander C., Leslie C.S., Marks D.S. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009, 27:549-555.
25. Fellmann C., Lowe S.W. Stable RNA interference rules for silencing. Nat Cell Biol 2014, 16:10-18.
26. Cuccato G., Polynikis A., Siciliano V., Graziano M., di Bernardo M., di Bernardo D. Modeling RNA interference in mammalian cells. BMC Syst Biol 2011, 5:19.
27. Mikhail A.S., Eetezadi S., Ekdawi S.N., Stewart J., Allen C. Image-based analysis of the size- and time-dependent penetration of polymeric micelles in multicellular tumor spheroids and tumor xenografts. Int J Pharm 2014, 464:168-177.
28. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
29. Nichols J.W., Bae Y.H. EPR: evidence fallacy. J Control Release 2014, 190:451-464.
30. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
31. Wang J., Lu Z., Gao Y., Wientjes M.G., Au J.L. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond) 2011, 6:1605-1620.
32. Sano K., Nakajima T., Choyke P.L., Kobayashi H. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 2013, 7:717-724.
33. Lu D., Wientjes M.G., Lu Z., Au J.L. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Therap 2007, 322:80-88.
34. Khawar I.A., Kim J.H., Kuh H.J. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release 2015, 201:78-89.
35. Philip B., Ito K., Moreno-Sanchez R., Ralph S.J. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013, 34:1699-1707.
36. Albini A., Bruno A., Gallo C., Pajardi G., Noonan D.M., Dallaglio K. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res 2015, 1-12.
37. Yu Y., Xiao C.H., Tan L.D., Wang Q.S., Li X.Q., Feng Y.M. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer 2014, 110:724-732.
38. Jung Y., Kim J.K., Shiozawa Y., Wang J., Mishra A., Joseph J., Berry J.E., McGee S., Lee E., Sun H., Wang J., Jin T., Zhang H., Dai J., Krebsbach P.H., Keller E.T., Pienta K.J., Taichman R.S. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013, 4:1795.
39. Plaks V., Kong N., Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell Stem Cell 2015, 16:225-238.
40. Pickup M., Novitskiy S., Moses H.L. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013, 13:788-799.
41. Tabassum D.P., Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer 2015, 15:473-483.
42. Zins K., Sioud M., Aharinejad S., Lucas T., Abraham D. Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy. Methods Mol Biol 2015, 1218:143-161.
43. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437.
44. Cai F., Li Z., Wang C., Xian S., Xu G., Peng F., Wei Y., Lu Y. Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model. BMB Rep 2013, 46:252-257.
45. Conde J., Bao C.C., Tan Y.Q., Cui D.X., Edelman E.R., Azevedo H.S., Byrne H.J., Artzi N., Tian F.R. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv Funct Mater 2015, 25:4183-4194.
46. Xu Z., Wang Y., Zhang L., Huang L. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 2014, 8:3636-3645.
47. Cheng C.J., Bahal R., Babar I.A., Pincus Z., Barrera F., Liu C., Svoronos A., Braddock D.T., Glazer P.M., Engelman D.M., Saltzman W.M., Slack F.J. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015, 518:107-110.
48. Liu J.Y., Chiang T., Liu C.H., Chern G.G., Lin T.T., Gao D.Y., Chen Y. Delivery of siRNA using CXCR4-targeted nanoparticles modulates tumor microenvironment and achieves a potent anti-tumor response in liver cancer. Mol Therap 2015.
49. Parvani J.G., Gujrati M.D., Mack M.A., Schiemann W.P., Lu Z.R. Silencing beta3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer. Cancer Res 2015, 75:2316-2325.
50. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012, 109:2784-2789.
51. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
52. Luo Z., Wang C., Yi H., Li P., Pan H., Liu L., Cai L., Ma Y. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Biomaterials 2015, 38:50-60.
53. Herrmann A., Priceman S.J., Swiderski P., Kujawski M., Xin H., Cherryholmes G.A., Zhang W., Zhang C., Lahtz C., Kowolik C., Forman S.J., Kortylewski M., Yu H. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest 2014, 124:2977-2987.
54. Bobrie A., Krumeich S., Reyal F., Recchi C., Moita L.F., Seabra M.C., Ostrowski M., Thery C. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res 2012, 72:4920-4930.
55. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
56. Peer D., Zhu P., Carman C.V., Lieberman J., Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 2007, 104:4095-4100.
57. Wittrup A., Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 2015, 16:543-552.
58. Conde J., Artzi N. Are RNAi and miRNA therapeutics truly dead?. Trends Biotechnol 2015, 33:141-144.
59. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
60. Coelho T., Adams D., Silva A., Lozeron P., Hawkins P.N., Mant T., Perez J., Chiesa J., Warrington S., Tranter E., Munisamy M., Falzone R., Harrop J., Cehelsky J., Bettencourt B.R., Geissler M., Butler J.S., Sehgal A., Meyers R.E., Chen Q., Borland T., Hutabarat R.M., Clausen V.A., Alvarez R., Fitzgerald K., Gamba-Vitalo C., Nochur S.V., Vaishnaw A.K., Sah D.W., Gollob J.A., Suhr O.B. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013, 369:819-829.
61. Martinez T., Gonzalez M.V., Roehl I., Wright N., Paneda C., Jimenez A.I. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Therap 2014, 22:81-91.